The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction
Open Access
- 5 October 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 8 (6), 1215-1226
- https://doi.org/10.1007/s13300-017-0302-3
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysisDiabetology & Metabolic Syndrome, 2013
- Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairmentVascular Health and Risk Management, 2013
- Clinical Pharmacokinetics and Pharmacodynamics of VildagliptinClinical Pharmacokinetics, 2012
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trialDiabetes, Obesity and Metabolism, 2011
- Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 DiabetesDiabetes Care, 2011
- Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in DiabetesJournal of the American Society of Nephrology, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocinLife Sciences, 2007
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003